Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 446.97 Million EUR | 1.11% |
| 2022 | 442.06 Million EUR | 56.72% |
| 2021 | 282.07 Million EUR | 54.95% |
| 2020 | 182.04 Million EUR | 286.72% |
| 2019 | 47.07 Million EUR | 244.9% |
| 2018 | 13.64 Million EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 389.79 Million EUR | 21.93% |
| 2024 Q2 | 319.68 Million EUR | -30.69% |
| 2024 Q1 | 461.24 Million EUR | 3.19% |
| 2023 FY | 446.97 Million EUR | 1.11% |
| 2023 Q3 | 478.29 Million EUR | -2.4% |
| 2023 Q4 | 446.97 Million EUR | -6.55% |
| 2023 Q2 | 490.06 Million EUR | -0.98% |
| 2023 Q1 | 494.91 Million EUR | 11.96% |
| 2022 Q4 | 442.06 Million EUR | -7.54% |
| 2022 FY | 442.06 Million EUR | 56.72% |
| 2022 Q3 | 478.09 Million EUR | -0.11% |
| 2022 Q2 | 478.62 Million EUR | 8.02% |
| 2022 Q1 | 443.09 Million EUR | 57.08% |
| 2021 Q2 | 202.44 Million EUR | 6.8% |
| 2021 Q4 | 282.07 Million EUR | 34.44% |
| 2021 Q3 | 209.82 Million EUR | 3.64% |
| 2021 FY | 282.07 Million EUR | 54.95% |
| 2021 Q1 | 189.54 Million EUR | 4.12% |
| 2020 FY | 182.04 Million EUR | 286.72% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | 182.04 Million EUR | 0.0% |
| 2019 FY | 47.07 Million EUR | 244.9% |
| 2018 FY | 13.64 Million EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AroCell AB (publ) | 11.24 Million SEK | -3874.506% |
| Devyser Diagnostics AB (publ) | 125 Million SEK | -257.578% |
| Immunovia AB (publ) | 31.69 Million SEK | -1310.454% |
| Prostatype Genomics AB (publ) | 24.54 Million SEK | -1720.812% |
| SenzaGen AB | 29.56 Million SEK | -1411.678% |
| Spermosens AB | 13.41 Million SEK | -3232.386% |